Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Evolva Holding SA
  6. News
  7. Summary
    EVE   CH0021218067

EVOLVA HOLDING SA

(EVE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Evolva provides financial and project update

02/09/2015 | 01:05am EST

Evolva provides financial and project update

9 February 2015 - Evolva (SIX: EVE) today provides a financial and project update.

According to the provisional, unaudited financials, revenues in 2014 slightly exceeded CHF 10 million (in line with guidance), whilst the year-end cash position of CHF 60.7 million was higher than the CHF 50 million projected in November 2014. This positive deviation is primarily due to transactions related to the acquisition of Allylix in December: the USD 4 million investment by Cargill and the sale of 6 million shares to cover Allylix liabilities that was executed earlier than expected (in December 2014). A major part of the proceeds from the share sale was used in January 2015 to settle the remaining Allylix liabilities. After adjusting for the above two factors, cash at year-end was about CHF 52.5 million compared with our guidance of CHF 50 million. Cash outflow from operations in 2014 developed in line with the November guidance ("about CHF 20 million").

In 2015, we expect revenues to increase on 2014. Product related revenues will contribute for the first time, however a significant majority of revenues will still derive from partnerships. Due to investment in manufacturing and commercialisation of key products, in particular stevia, resveratrol and nootkatone, our operating cash outflow will increase in 2015.

We expect the recent appreciation of the Swiss Franc to be modestly positive for Evolva in the short term, given that we have significant costs in other currencies. The beneficial cost impact outweighs some negative effect on revenues.

On stevia, a decision on exercising our option to participate up to 45% in Cargill's fermented stevia business is expected in the first half of 2015. We expect that stevia will be launched in 2016.

The portfolio review initiated after the Allylix acquisition is ongoing and is expected to conclude with respect to our major products in March 2015.

Evolva will publish its audited financial statements for 2014, as well as a more detailed financial outlook for 2015, on Tuesday 31 March 2015. The Annual General Meeting will take place on Tuesday 12 May 2015 in the morning in Basel, Switzerland.

- ends -

About Evolva Holding SA

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva's products include stevia, vanillin, nootkatone, valencene, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.

Contact Details

Neil Goldsmith, CEO

Jakob Dynnes Hansen, CFO

Paul Verbraeken, IR

neilg@evolva.com

jakobdh@evolva.com

paulv@evolva.com

+ 41 61 485 2005

+ 41 61 485 2034

+ 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.




Provider
Channel
Contact
Tensid Ltd., Switzerland
www.tensid.ch


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50
All news about EVOLVA HOLDING SA
11/30Evolva To Raise $8 Million Via Private Placement
MT
11/30Evolva CFO to Step Down
MT
11/30Evolva announces private placement of 63.8m shares to VERAISON raising gross proceeds o..
EQ
11/30Evolva Holding SA Announces the Departure of Carsten Daweritz as Cfo, Effective May 31,..
CI
09/27EVOLVA : Issues 40 Million New Shares
MT
09/10EVOLVA : HY 2021 Results Presentation (EN)
PU
08/26Evolva Holding Sa Reports Earnings Results for the Half Year Ended June 30, 2021
CI
08/26EVOLVA : Consolidated financial statement HY 2021 (EN)
PU
08/26EVOLVA : Forecasts Return to Profit in Q4 After H1 Operating Loss Doubles
MT
08/26EVOLVA : Half Year Results presentation 2021 (EN)
PU
More news
Analyst Recommendations on EVOLVA HOLDING SA
More recommendations
Financials
Sales 2021 13,8 M 14,9 M 14,9 M
Net income 2021 -25,1 M -27,2 M -27,2 M
Net cash 2021 4,59 M 4,98 M 4,98 M
P/E ratio 2021 -4,87x
Yield 2021 -
Capitalization 127 M 138 M 138 M
EV / Sales 2021 8,91x
EV / Sales 2022 4,86x
Nbr of Employees 65
Free-Float 86,2%
Chart EVOLVA HOLDING SA
Duration : Period :
Evolva Holding SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOLVA HOLDING SA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 0,14 CHF
Average target price 0,28 CHF
Spread / Average Target 91,2%
EPS Revisions
Managers and Directors
Oliver Walker Chief Executive & Financial Officer
Beat In-Albon Chairman
Astrid Schäfer Head-Research & Development
Gerhard Lobmaier Chief Operating Officer
Nic Buergin Secretary, Head-Legal & Compliance
Sector and Competitors
1st jan.Capi. (M$)
EVOLVA HOLDING SA-22.87%150
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-40.67%24 625